Literature DB >> 8035042

Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.

E Cambau1, W Sougakoff, M Besson, C Truffot-Pernot, J Grosset, V Jarlier.   

Abstract

A strain of Mycobacterium tuberculosis resistant to ofloxacin was selected in a patient with a long history of multidrug-resistant tuberculosis eventually treated by ofloxacin combined with other second-line drugs. A mutation in the gyrA gene was hypothesized to be the mechanism of acquired resistance to ofloxacin in this strain. Chromosomal DNA of strains MTB1, isolated before treatment and susceptible to ofloxacin (MIC, 1 microgram/mL), and MTB2, isolated during treatment and resistant to ofloxacin (MIC, 32 micrograms/mL), was amplified by polymerase chain reaction (PCR) using two oligonucleotide primers highly homologous to DNA sequences flanking the quinolone resistance-determining region in gyrA of mycobacteria. Comparison of the nucleotide sequences of the 150-bp fragments obtained by PCR revealed a point mutation in MTB2 leading to the substitution of histidine for aspartic acid at a position corresponding to residues involved in quinolone resistance in Escherichia coli (Asp87), Staphylococcus aureus (Glu88), and Campylobacter jejuni (Asp90).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035042     DOI: 10.1093/infdis/170.2.479

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay.

Authors:  K Hirano; C Abe; M Takahashi
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

Review 2.  Tuberculosis: 9. Treatment.

Authors:  E Hershfield
Journal:  CMAJ       Date:  1999-08-24       Impact factor: 8.262

Review 3.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes.

Authors:  Jean-Noël Dauendorffer; Isabelle Guillemin; Alexandra Aubry; Chantal Truffot-Pernot; Wladimir Sougakoff; Vincent Jarlier; Emmanuelle Cambau
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

Review 5.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

Review 6.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

7.  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Authors:  Alexandra Aubry; Nicolas Veziris; Emmanuelle Cambau; Chantal Truffot-Pernot; Vincent Jarlier; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 8.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

9.  Nonradioactive single-strand conformation polymorphism analysis for detection of fluoroquinolone resistance in mycobacteria.

Authors:  W Sougakoff; N Lemaître; E Cambau; M Szpytma; V Revel; V Jarlier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

10.  Sequence of quinolone resistance-determining region of gyrA gene for clinical isolates and for an in vitro-selected quinolone-resistant strain of Coxiella burnetii.

Authors:  D Musso; M Drancourt; S Osscini; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.